For B-cell-driven malignancies, Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, remains a primary therapeutic target. Covalent BTK inhibitors (cBTKi), while clinically used, still experience therapeutic limitations due to unwanted side effects beyond the intended target, oral ...